Phase 3 Data: Upadacitinib Shows Long-term Safety and Efficacy in Adolescents With AD
Adolescents with moderate to severe atopic dermatitis (AD) continue to do well on upadacitinib (Rinvoq, AbbVie) for up to 76 weeks with no new safety signals, according to data from three Phase 3 randomized clinical trials published in JAMA Dermatology. Fully 542 adolescents aged 12 to 17 received once-daily upadacitinib (15mg or 30mg) with or […]